MannKind’s fair value estimate is held at US$7.50, signaling that the core price target framework is intact even as some inputs to the model are tweaked. Recent Street commentary helps explain why ...
SILVER SPRING, Md. & RESEARCH TRIANGLE PARK, N.C., March 11, 2026--United Therapeutics Corporation (Nasdaq: UTHR), a public ...
SILVER SPRING, Md. & RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)-- United Therapeutics Corporation (UTHR), a public benefit corporation, today announced that its TETON-2 study evaluating the use of ...
Second registration study of Tyvaso® (treprostinil) Inhalation Solution for patients with IPF Subjects will be randomly allocated 1:1 to receive Tyvaso or placebo. All subjects will initiate Tyvaso or ...
Zacks Investment Research on MSN
United Therapeutics stock surges 32% in 6 months: Here's why
Shares of United Therapeutics UTHR have surged approximately 32% over the past six months, driven by strong commercial growth ...
United Therapeutics UTHR announced full enrolment in the phase III TETON 2 study evaluating a nebulized version of Tyvaso (treprostinil) in patients with idiopathic pulmonary fibrosis (IPF), a ...
SILVER SPRING, Md. & RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--United Therapeutics Corporation (Nasdaq: UTHR), a public benefit corporation, announced today that the U.S. Food and Drug ...
Shares of United Therapeutics climbed after the company said it planned to release a new soft mist inhaler to treat certain lung diseases next year. The stock rose 9%, to $515.94, midday Wednesday and ...
Is Tyvaso Right for My PAH? To know if Tyvaso is right for you, your health care provider will look at your medical history, including the type of pulmonary hypertension you have, your symptoms, other ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results